Observation of Clinical Efficacy of Huang Kuí Capsules Combined with Valsartan in Reducing the Nephrotoxicity of Bevacizumab
Objective To observe the clinical efficacy of Huangkui Capsules,valsartan,and their combination in the treatment of proteinuria and hypertension in patients with recurrent or advanced tumors following treatment with bevacizumab.Methods 160 patients with late-stage or recurrent lung adenocarcinoma,colorectal cancer,ovarian cancer,cervical cancer,or hepatocellular carcinoma who developed hypertension or proteinuria after bevacizumab treatment were randomly divided into 4 groups.Group A received placebo,Group B received oral Huangkui Capsules,Group C received oral valsartan capsules,and Group D received combined treatment with Huangkui Capsules and valsartan.Blood pressure and urinary protein levels were observed af-ter 6 and 12 weeks of treatment.Results After bevacizumab treatment,the blood pressure in Group A was(145.34±9.87/89.67±9.32)mmHg,and after placebo treatment for 12 weeks,it was(149.08±8.23/92.49±8.92)mmHg.In Group B,the blood pressure after bevacizumab treatment was(149.19±8.63/90.71±8.89)mmHg,and after Huangkui Capsules treatment for 12 weeks,it was(150.08±7.73/92.71±7.74)mmHg.In Group C,the blood pressure after bevacizumab treatment was(147.78±9.54/91.98±8.01)mmHg,and after valsartan treatment for 12 weeks,it was(118.46±8.13/68.01±6.45)mmHg,P＜0.05.In Group D,the blood pressure after bevacizumab treatment was(150.65±7.63/89.73±7.84)mmHg,and after valsartan treatment for 12 weeks,it was(108.08±8.76/60.71±7.29)mmHg,P＜0.05.After bevacizumab treatment,the urinary protein in Group A was(998.48±65.56)mg/24h,and after placebo treatment for 12 weeks,it was(1120.5±39.71)mg/24h.In Group B,the urinary protein after bevacizumab treatment was(986.53±48.97)mg/24 h,and after Huangkui Capsules treatment for 12 weeks,it was(260.3±32.51)mg/24 h,P＜0.05.In Group C,the urinary protein after bevacizumab treatment was(1020.03±55.91)mg/24 h,and after valsartan treatment for 12 weeks,it was(265.21±32.73)mg/24 h,P＜0.05.In Group D,the urinary protein after bevacizumab treatment was(1054±49.78)mg/24h,and after valsartan treatment for 12 weeks,it was(59.17±11.52)mg/24 h,P＜0.05.Conclusion Huangkui Capsules combined with valsartan can significantly reduce bevacizumab-relat-ed hypertension and proteinuria,thereby reducing its renal toxicity.
Huang Kui capsulesValsartanBevacizumabBlood pressureUrinary protein
NETL
NSTL
万方数据
